Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) – Equities research analysts at HC Wainwright raised their Q1 2023 earnings estimates for shares of Timber Pharmaceuticals in a note issued to investors on Monday, April 10th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.17) per share for the quarter, […]